Tumor tissue analysis showed that two patients with the loss-of-function Y139X variant exhibited lower mRNA expression of the mutant allele, lower CHK2 expression, and lower p53 and phosphorylated p53 expression than in patients with sporadic PTC (WT CHEK2). Here, CHEK2 is linked to neoplasm.